BR112021013157A8 - Usos de um inibidor de nrp-1, uso de uma combinação, uso de um anticorpo multiespecífico, método ex vivo para predizer, uso de um inibidor, anticorpo multiespecífico, população de células modificadas, método ex vivo de produção e uso de uma população de células t - Google Patents
Usos de um inibidor de nrp-1, uso de uma combinação, uso de um anticorpo multiespecífico, método ex vivo para predizer, uso de um inibidor, anticorpo multiespecífico, população de células modificadas, método ex vivo de produção e uso de uma população de células tInfo
- Publication number
- BR112021013157A8 BR112021013157A8 BR112021013157A BR112021013157A BR112021013157A8 BR 112021013157 A8 BR112021013157 A8 BR 112021013157A8 BR 112021013157 A BR112021013157 A BR 112021013157A BR 112021013157 A BR112021013157 A BR 112021013157A BR 112021013157 A8 BR112021013157 A8 BR 112021013157A8
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- antibody
- inhibitor
- multiespecific
- nrp1
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 abstract 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 102000004207 Neuropilin-1 Human genes 0.000 abstract 3
- 108090000772 Neuropilin-1 Proteins 0.000 abstract 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 abstract 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 abstract 2
- 230000005975 antitumor immune response Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 241000282412 Homo Species 0.000 abstract 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 101150051337 NRP1 gene Proteins 0.000 abstract 1
- 102100028762 Neuropilin-1 Human genes 0.000 abstract 1
- 230000006023 anti-tumor response Effects 0.000 abstract 1
- 230000001461 cytolytic effect Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005746 immune checkpoint blockade Effects 0.000 abstract 1
- 229940126546 immune checkpoint molecule Drugs 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 208000021039 metastatic melanoma Diseases 0.000 abstract 1
- 229960002621 pembrolizumab Drugs 0.000 abstract 1
- 230000002269 spontaneous effect Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 210000000225 synapse Anatomy 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
Abstract
USOS DE UM INIBIDOR DE NRP-1, USO DE UMA COMBINAÇÃO, USO DE UM ANTICORPO MULTIESPECÍFICO, MÉTODO EX VIVO PARA PREDIZER, USO DE UM INIBIDOR, ANTICORPO MULTIESPECÍFICO, POPULAÇÃO DE CÉLULAS MODIFICADAS, MÉTODO EX VIVO DE PRODUÇÃO E USO DE UMA POPULAÇÃO DE CÉLULAS T. O uso de terapias que visam pontos de controle imunológicos, tal como a morte celular programada 1 (PD1), melhorou a sobrevida em pacientes com câncer pela liberação células T CD8+ exauridas, restaurando assim as respostas imunes antitumorais. Entretanto, a maioria dos pacientes apresenta recidiva ou é refratária às terapias de bloqueio do ponto de controle imunológico. Na presente divulgação, os inventores demonstraram que NRP1 é recrutado na sinapse citolítica de células T PD1+ CD8+, e interage e aumenta a atividade de PD-1. Em camundongos, a deleção específica de Nrp1 em células T CD8+ melhora as respostas imunes espontâneas e antitumorais do anticorpo anti-PD1. Da mesma forma, no melanoma metastático humano, a expressão de NRP1 em células T CD8+ infiltrantes de tumor prediz um resultado ruim de pacientes tratados com anti-PD1 (por exemplo, com pembrolizumabe). Finalmente, a combinação de anticorpos anti-NRP1 e anti-PD1 é sinérgica em humanos, especificamente na resposta antitumoral de células T CD8+. Assim, a inibição terapêutica de NRP1 sozinha ou combinada com um inibidor do ponto de controle imunológico (por exemplo, anticorpo anti-PD1) poderia reprimir de forma eficiente o crescimento do tumor no câncer humano. A presente invenção também diz respeito a anticorpos multiespecíficos compreendendo pelo menos um sítio de ligação que se liga especificamente a uma molécula do ponto de controle imunológico (por exemplo, PD-1), e pelo menos um sítio de ligação que se liga especificamente à NRP-1. A presente invenção também diz respeito a uma população de células manipuladas para expressar um receptor de antígeno quimérico (CAR), em que a expressão de NRP-1 nas referidas células é reprimida.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19305003.6 | 2019-01-03 | ||
EP19305003 | 2019-01-03 | ||
PCT/EP2020/050039 WO2020141199A1 (en) | 2019-01-03 | 2020-01-02 | Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112021013157A2 BR112021013157A2 (pt) | 2021-09-14 |
BR112021013157A8 true BR112021013157A8 (pt) | 2022-12-06 |
Family
ID=65200739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021013157A BR112021013157A8 (pt) | 2019-01-03 | 2020-01-02 | Usos de um inibidor de nrp-1, uso de uma combinação, uso de um anticorpo multiespecífico, método ex vivo para predizer, uso de um inibidor, anticorpo multiespecífico, população de células modificadas, método ex vivo de produção e uso de uma população de células t |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220073626A1 (pt) |
EP (2) | EP3906415A1 (pt) |
JP (1) | JP2022517324A (pt) |
KR (1) | KR20220008253A (pt) |
CN (1) | CN113574386A (pt) |
AU (1) | AU2020205150A1 (pt) |
BR (1) | BR112021013157A8 (pt) |
CA (1) | CA3125476A1 (pt) |
IL (1) | IL284556A (pt) |
MX (1) | MX2021008121A (pt) |
SG (1) | SG11202107257UA (pt) |
WO (1) | WO2020141199A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4304613A1 (en) * | 2021-03-09 | 2024-01-17 | Mayo Foundation for Medical Education and Research | Biomarkers for identifying and treating cancer patients |
WO2024052233A1 (en) * | 2022-09-07 | 2024-03-14 | Novigenix Sa | Methods to predict response to immunotherapy in metastatic melanoma |
WO2024055010A1 (en) * | 2022-09-08 | 2024-03-14 | Board Of Regents, The University Of Texas System | Compositions for treating cancer and methods of using the same |
CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
Family Cites Families (150)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US366A (en) | 1837-08-31 | Quadrant hinge foe | ||
US6649A (en) | 1849-08-14 | Arrangement of steam-boiler | ||
US5866A (en) | 1848-10-17 | Dentist s deill | ||
US69A (en) | 1836-10-27 | Machine eor picking or breaking wool and ginned or seedless cotton | ||
US6927A (en) | 1849-12-04 | Improvement in pumps for raising water | ||
US138A (en) | 1837-03-08 | Barnabas s | ||
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4888278A (en) | 1985-10-22 | 1989-12-19 | University Of Massachusetts Medical Center | In-situ hybridization to detect nucleic acid sequences in morphologically intact cells |
US6280929B1 (en) | 1986-01-16 | 2001-08-28 | The Regents Of The University Of California | Method of detecting genetic translocations identified with chromosomal abnormalities |
US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4774339A (en) | 1987-08-10 | 1988-09-27 | Molecular Probes, Inc. | Chemically reactive dipyrrometheneboron difluoride dyes |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5132432A (en) | 1989-09-22 | 1992-07-21 | Molecular Probes, Inc. | Chemically reactive pyrenyloxy sulfonic acid dyes |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5433896A (en) | 1994-05-20 | 1995-07-18 | Molecular Probes, Inc. | Dibenzopyrrometheneboron difluoride dyes |
US5274113A (en) | 1991-11-01 | 1993-12-28 | Molecular Probes, Inc. | Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5248782A (en) | 1990-12-18 | 1993-09-28 | Molecular Probes, Inc. | Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes |
US5338854A (en) | 1991-02-13 | 1994-08-16 | Molecular Probes, Inc. | Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes |
US5427932A (en) | 1991-04-09 | 1995-06-27 | Reagents Of The University Of California | Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using |
US5187288A (en) | 1991-05-22 | 1993-02-16 | Molecular Probes, Inc. | Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5262357A (en) | 1991-11-22 | 1993-11-16 | The Regents Of The University Of California | Low temperature thin films formed from nanocrystal precursors |
US5505928A (en) | 1991-11-22 | 1996-04-09 | The Regents Of University Of California | Preparation of III-V semiconductor nanocrystals |
CA2122732C (en) | 1991-11-25 | 2008-04-08 | Marc D. Whitlow | Multivalent antigen-binding proteins |
ATE452207T1 (de) | 1992-08-21 | 2010-01-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
US6048616A (en) | 1993-04-21 | 2000-04-11 | Philips Electronics N.A. Corp. | Encapsulated quantum sized doped semiconductor particles and method of manufacturing same |
US5472842A (en) | 1993-10-06 | 1995-12-05 | The Regents Of The University Of California | Detection of amplified or deleted chromosomal regions |
EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
US5571018A (en) | 1994-11-23 | 1996-11-05 | Motorola, Inc. | Arrangement for simulating indirect fire in combat training |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5690807A (en) | 1995-08-03 | 1997-11-25 | Massachusetts Institute Of Technology | Method for producing semiconductor particles |
US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
US5800996A (en) | 1996-05-03 | 1998-09-01 | The Perkin Elmer Corporation | Energy transfer dyes with enchanced fluorescence |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US5830912A (en) | 1996-11-15 | 1998-11-03 | Molecular Probes, Inc. | Derivatives of 6,8-difluoro-7-hydroxycoumarin |
US5696157A (en) | 1996-11-15 | 1997-12-09 | Molecular Probes, Inc. | Sulfonated derivatives of 7-aminocoumarin |
US5866366A (en) | 1997-07-01 | 1999-02-02 | Smithkline Beecham Corporation | gidB |
US6130101A (en) | 1997-09-23 | 2000-10-10 | Molecular Probes, Inc. | Sulfonated xanthene derivatives |
US6322901B1 (en) | 1997-11-13 | 2001-11-27 | Massachusetts Institute Of Technology | Highly luminescent color-selective nano-crystalline materials |
US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US5990479A (en) | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
US6617583B1 (en) | 1998-09-18 | 2003-09-09 | Massachusetts Institute Of Technology | Inventory control |
US6114038A (en) | 1998-11-10 | 2000-09-05 | Biocrystal Ltd. | Functionalized nanocrystals and their use in detection systems |
US6855202B2 (en) | 2001-11-30 | 2005-02-15 | The Regents Of The University Of California | Shaped nanocrystal particles and methods for making the same |
US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
US6274323B1 (en) | 1999-05-07 | 2001-08-14 | Quantum Dot Corporation | Method of detecting an analyte in a sample using semiconductor nanocrystals as a detectable label |
US7214477B1 (en) | 1999-07-26 | 2007-05-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Layered device with capture regions for cellular analysis |
US7838222B2 (en) | 1999-07-26 | 2010-11-23 | United States of America/ NIH | Methods, devices and kits for multiplex blotting of biological samples from multi-well plates |
ATE328277T1 (de) | 1999-07-26 | 2006-06-15 | Us Gov Health & Human Serv | Schichtvorrichtung mit einfangbereichen zur zellulären analyse |
US6969615B2 (en) | 1999-07-26 | 2005-11-29 | 20/20 Genesystems, Inc. | Methods, devices, arrays and kits for detecting and analyzing biomolecules |
CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US6306736B1 (en) | 2000-02-04 | 2001-10-23 | The Regents Of The University Of California | Process for forming shaped group III-V semiconductor nanocrystals, and product formed using process |
US6225198B1 (en) | 2000-02-04 | 2001-05-01 | The Regents Of The University Of California | Process for forming shaped group II-VI semiconductor nanocrystals, and product formed using process |
WO2001071043A1 (en) | 2000-03-22 | 2001-09-27 | Quantum Dot Corporation | Loop probe hybridization assay for polynucleotide analysis |
JP2003535063A (ja) | 2000-06-01 | 2003-11-25 | ザ・ボード・オブ・リージェンツ・フォー・オクラホマ・ステート・ユニバーシティー | 放射線医薬としてのナノ粒子のバイオコンジュゲート |
US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
CA2417816A1 (en) | 2000-08-04 | 2002-02-14 | Molecular Probes, Inc. | Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings |
US6942970B2 (en) | 2000-09-14 | 2005-09-13 | Zymed Laboratories, Inc. | Identifying subjects suitable for topoisomerase II inhibitor treatment |
US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
US20020083888A1 (en) | 2000-12-28 | 2002-07-04 | Zehnder Donald A. | Flow synthesis of quantum dot nanocrystals |
US6670113B2 (en) | 2001-03-30 | 2003-12-30 | Nanoprobes | Enzymatic deposition and alteration of metals |
US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
US6709929B2 (en) | 2001-06-25 | 2004-03-23 | North Carolina State University | Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
CA2453450A1 (en) | 2001-07-20 | 2003-11-06 | Quantum Dot Corporation | Luminescent nanoparticles and methods for their preparation |
WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
GB0229734D0 (en) | 2002-12-23 | 2003-01-29 | Qinetiq Ltd | Grading oestrogen and progesterone receptors expression |
US7257268B2 (en) | 2003-02-28 | 2007-08-14 | Aperio Technologies, Inc. | Systems and methods for image pattern recognition |
ES2428941T3 (es) | 2003-03-10 | 2013-11-12 | Expression Pathology, Inc. | Preparación líquida de tejidos a partir de muestras biológicas, tejidos y células procesadas histopatológicamente |
US7642064B2 (en) | 2003-06-24 | 2010-01-05 | Ventana Medical Systems, Inc. | Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest |
DK1636586T3 (da) | 2003-06-24 | 2009-11-23 | Ventana Med Syst Inc | Enzymkatalyseret metaldeponering til foröget in situ-detektion af immunhistokemisker epitoper og nucleinsyresekvenser |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
EP1893241A2 (en) | 2005-04-28 | 2008-03-05 | Ventana Medical Systems, Inc. | Fluorescent nanoparticles conjugated to antibodies via a peg linker |
WO2006116628A2 (en) | 2005-04-28 | 2006-11-02 | Ventana Medical Systems, Inc. | Enzymes conjugated to antiobodies via a peg heterobifuctional linker |
EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
UA96139C2 (uk) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
US20070117153A1 (en) | 2005-11-23 | 2007-05-24 | Christopher Bieniarz | Molecular conjugate |
US8986926B2 (en) | 2005-12-23 | 2015-03-24 | Nanostring Technologies, Inc. | Compositions comprising oriented, immobilized macromolecules and methods for their preparation |
JP5537034B2 (ja) | 2005-12-23 | 2014-07-02 | ナノストリング テクノロジーズ,インコーポレーテッド | ナノレポーターならびにその作製方法および使用方法 |
US7741045B2 (en) | 2006-11-16 | 2010-06-22 | General Electric Company | Sequential analysis of biological samples |
US7629125B2 (en) | 2006-11-16 | 2009-12-08 | General Electric Company | Sequential analysis of biological samples |
MX2009010282A (es) | 2007-03-29 | 2009-10-12 | Genmab As | Anticuerpos biespecificos y metodos para su produccion. |
AU2008237018B2 (en) | 2007-04-10 | 2014-04-03 | Nanostring Technologies, Inc. | Methods and computer systems for identifying target-specific sequences for use in nanoreporters |
US8023714B2 (en) | 2007-06-06 | 2011-09-20 | Aperio Technologies, Inc. | System and method for assessing image interpretability in anatomic pathology |
EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
WO2010019826A1 (en) | 2008-08-14 | 2010-02-18 | Nanostring Technologies, Inc | Stable nanoreporters |
CN102165489B (zh) | 2008-09-16 | 2015-11-25 | 赫斯托克斯公司 | 生物标志物表达的可再现量化 |
CN108484767B (zh) | 2008-09-26 | 2022-01-14 | 达纳-法伯癌症研究公司 | 人抗pd-1、pd-l1和pd-l2的抗体及其应用 |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
WO2010083252A2 (en) | 2009-01-14 | 2010-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ratio based biomarkers and methods of use thereof |
EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
US8647623B2 (en) | 2009-04-10 | 2014-02-11 | Kyowa Hakko Kirin Co., Ltd | Method for treatment of blood tumor using anti-TIM-3 antibody |
US20110111435A1 (en) | 2009-11-06 | 2011-05-12 | SlidePath Limited | Detecting Cell Surface Markers |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
KR102152109B1 (ko) | 2010-04-20 | 2020-09-07 | 젠맵 에이/에스 | 이종이량체 항체 fc-함유 단백질 및 그의 생산 방법 |
ES2682078T3 (es) | 2010-06-11 | 2018-09-18 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo anti-TIM-3 |
WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
US9783578B2 (en) | 2010-06-25 | 2017-10-10 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
US9096642B2 (en) | 2011-06-08 | 2015-08-04 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
GB201203071D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
EP2822957A1 (en) | 2012-03-07 | 2015-01-14 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
MX2014011353A (es) | 2012-03-29 | 2014-12-05 | Aurigene Discovery Tech Ltd | Inmunomodulacion de compuestos ciclicos del bucle bc de muerte celular programada (pd1) humana. |
EP4289948A3 (en) | 2012-05-25 | 2024-04-17 | The Regents of the University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
EP2903692B1 (en) * | 2012-10-08 | 2019-12-25 | St. Jude Children's Research Hospital | Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis |
US20140189896A1 (en) | 2012-12-12 | 2014-07-03 | Feng Zhang | Crispr-cas component systems, methods and compositions for sequence manipulation |
ES2786193T3 (es) | 2012-12-12 | 2020-10-09 | Broad Inst Inc | Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
WO2014150677A1 (en) | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase (ido) |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
HUP1300432A2 (hu) | 2013-07-10 | 2015-01-28 | Tamas Kardos | Downhill kerékpár szerkezet javított felfüggesztéssel |
EA030155B1 (ru) | 2013-09-06 | 2018-06-29 | Ауриген Дискавери Текнолоджиз Лимитед | Производные 1,2,4-оксадиазола в качестве иммуномодуляторов |
TR201811077T4 (tr) | 2013-09-06 | 2018-08-27 | Aurigene Discovery Tech Ltd | İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri. |
WO2015036927A1 (en) | 2013-09-10 | 2015-03-19 | Aurigene Discovery Technologies Limited | Immunomodulating peptidomimetic derivatives |
US20160237455A1 (en) | 2013-09-27 | 2016-08-18 | Editas Medicine, Inc. | Crispr-related methods and compositions |
PL3177644T3 (pl) | 2014-08-05 | 2021-06-14 | MabQuest SA | Immunologiczne reagenty wiążące do PD-1 |
WO2017055404A1 (en) * | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
WO2017075451A1 (en) * | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2018087143A2 (en) * | 2016-11-08 | 2018-05-17 | Actigen Ltd | Anti-pd-1 antibodies |
JOP20190134A1 (ar) * | 2016-12-23 | 2019-06-02 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها |
CA3063893A1 (en) * | 2017-05-16 | 2018-11-22 | Immunogen, Inc. | Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations |
AU2018277559A1 (en) * | 2017-05-30 | 2019-10-17 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent |
WO2018223182A1 (en) * | 2017-06-05 | 2018-12-13 | The Council Of The Queensland Institute Of Medical Research | A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf- kb ligand) antagonist for cancer therapy or prophylaxis and uses therefor. |
EP3887399A1 (en) * | 2018-11-30 | 2021-10-06 | Institut Gustave-Roussy | Anti-neuropilin-1 and anti-programmed cell death-1 combination therapy for treating cancer |
-
2020
- 2020-01-02 WO PCT/EP2020/050039 patent/WO2020141199A1/en unknown
- 2020-01-02 AU AU2020205150A patent/AU2020205150A1/en active Pending
- 2020-01-02 EP EP20700002.7A patent/EP3906415A1/en active Pending
- 2020-01-02 MX MX2021008121A patent/MX2021008121A/es unknown
- 2020-01-02 JP JP2021539056A patent/JP2022517324A/ja active Pending
- 2020-01-02 BR BR112021013157A patent/BR112021013157A8/pt unknown
- 2020-01-02 CN CN202080008095.5A patent/CN113574386A/zh active Pending
- 2020-01-02 KR KR1020217020858A patent/KR20220008253A/ko active Search and Examination
- 2020-01-02 EP EP22157031.0A patent/EP4059569A1/en active Pending
- 2020-01-02 SG SG11202107257UA patent/SG11202107257UA/en unknown
- 2020-01-02 CA CA3125476A patent/CA3125476A1/en active Pending
- 2020-01-02 US US17/420,537 patent/US20220073626A1/en active Pending
-
2021
- 2021-07-01 IL IL284556A patent/IL284556A/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202107257UA (en) | 2021-07-29 |
IL284556A (en) | 2021-08-31 |
EP3906415A1 (en) | 2021-11-10 |
EP4059569A1 (en) | 2022-09-21 |
MX2021008121A (es) | 2021-12-10 |
CN113574386A (zh) | 2021-10-29 |
JP2022517324A (ja) | 2022-03-08 |
AU2020205150A8 (en) | 2021-09-02 |
KR20220008253A (ko) | 2022-01-20 |
AU2020205150A1 (en) | 2021-07-22 |
WO2020141199A1 (en) | 2020-07-09 |
US20220073626A1 (en) | 2022-03-10 |
BR112021013157A2 (pt) | 2021-09-14 |
CA3125476A1 (en) | 2020-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021013157A8 (pt) | Usos de um inibidor de nrp-1, uso de uma combinação, uso de um anticorpo multiespecífico, método ex vivo para predizer, uso de um inibidor, anticorpo multiespecífico, população de células modificadas, método ex vivo de produção e uso de uma população de células t | |
Koury et al. | Immunotherapies: exploiting the immune system for cancer treatment | |
Antonia et al. | Immunotherapy: beyond anti–PD-1 and anti–PD-L1 therapies | |
Vignard et al. | Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells | |
Park et al. | Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL | |
BR112018071199A2 (pt) | célula t, população isolada de células t, composição farmacêutica, método de tratamento, método para gerar uma célula t, vetor, célula tronco | |
BR112018012794A2 (pt) | receptor de célula t, tcr que se liga a um complexo hla-a*02 sllmwitqc, fusão anti-cd3 de tcr, ácido nucléico, vetor de expressão, célula que ocorre e/ou purificada e/ou concebida de maneira não natural, célula, composição farmacêutica, método de tratamento de um indivíduo humano, formulação injetável para administração a um indivíduo humano, e método de produção de uma tcr | |
BR112019001818A2 (pt) | terapia combinada para câncer | |
BR112021008930A2 (pt) | Métodos e combinações para o tratamento e modulação de célula t | |
BR112018005445A2 (pt) | anticorpos biespecíficos anti-cd3 otimizados e usos dos mesmos | |
BR112018067679A2 (pt) | células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso | |
BR112019001570A2 (pt) | terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1 | |
EA201992131A1 (ru) | Высокоаффинные специфичные к mage-a1 tcr и их применение | |
BR112017001183A2 (pt) | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado | |
BR122020025496B8 (pt) | Método de produção de uma célula imune modificada, em que a célula imune é uma célula t alogênica ou autóloga | |
BR112017019343A2 (pt) | uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas | |
BR112021008774A2 (pt) | Formulação farmacêutica, agente de ligação, métodos para tratamento de uma doença, para produzir uma formulação farmacêutica, para induzir a morte celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, uso de uma formulação farmacêutica | |
Schirrmacher et al. | Strong T‑cell costimulation can reactivate tumor antigen‑specific T cells in late‑stage metastasized colorectal carcinoma patients: Results from a phase Ⅰ clinical study | |
CL2022001715A1 (es) | Tratamiento que involucra células efectoras inmunitarias modificadas genéticamente para expresar receptores de antígenos | |
Valdés et al. | Cell-cycle-dependent regulation of CNT1, a concentrative nucleoside transporter involved in the uptake of cell-cycle-dependent nucleoside-derived anticancer drugs | |
Wang et al. | Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor | |
Bakacs et al. | Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency | |
Carrette et al. | NKG2A blocks the anti-metastatic functions of natural killer cells | |
BR112018068135A2 (pt) | conformador aberto de hla-b57 | |
Huarte et al. | Prophylactic itacitinib (INCB039110) for the prevention of cytokine release syndrome induced by chimeric antigen receptor T-cells (CAR-T-cells) therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) ; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; FONDATION IMAGINE (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) ; UNIVERSITE PARIS-SACLAY (FR) ; UNIVERSITE PARIS CITE (FR) |